Novel breast cancer therapy candidate Alpha-TEA enters clinical study
We're excited to announce a new clinical trail for advanced stage HER2+ breast cancer, in partnership with Veana Therapeutics. The trial combines a small molecule called alpha-TEA with the HER2-specific trastuzumab monoclonal antibody, to kick the immune system into high gear and destroy cancer! We are moving the needle on new treatments for breast cancer. Learn more about our clinical study here.